Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT-709478 is a potent, selective T-type calcium channel blocker that is orally active and capable of penetrating the brain. It is currently utilized in research focusing on generalized epilepsies[1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 945 | 5日内发货 | ||
5 mg | ¥ 1,580 | 5日内发货 | ||
25 mg | ¥ 4,970 | 6-8周 | ||
50 mg | ¥ 6,590 | 6-8周 | ||
100 mg | ¥ 11,200 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 5日内发货 |
产品描述 | ACT-709478 is a potent, selective T-type calcium channel blocker that is orally active and capable of penetrating the brain. It is currently utilized in research focusing on generalized epilepsies[1]. |
靶点活性 | Cav 3.1:6.4 nM, Cav 3.2:18 nM, Cav 3.3:7.5 nM, Cav 1.2:2410 nM |
体外活性 | ACT-709478 (Compound 66b) blocks Cav3.1, Cav3.2, Cav3.3, Cav1.2 with IC50s of 6.4, 18, 7.5 and 2410 nM, respectively. ACT-709478 blocks recombinant channel hCav3.3 potently with marked voltage-dependency (Kr≈1500 nM and Ki≈20 nM). ACT-709478 blocks currents through hKv11.1-hERG channels with an IC50 of 5.5 μM[1]. ACT-709478 also inhibits P450 enzymes with IC50s of 14, 15, 22, 25, 51 and 52 μM for CYP2C8,CYP2D6 CYP2C9, CYP2C19, CYP3A4, and CYP2B6, respectively[1]. |
体内活性 | ACT-709478 ( 100, 300 mg/kg, p.o., 12 hours) can decreas the cumulative duration of absence-like seizures in mice[1]. |
分子量 | 425.41 |
分子式 | C22H18F3N5O |
CAS No. | 1838651-58-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (293.83 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3507 mL | 11.7534 mL | 23.5067 mL | 58.7668 mL |
5 mM | 0.4701 mL | 2.3507 mL | 4.7013 mL | 11.7534 mL | |
10 mM | 0.2351 mL | 1.1753 mL | 2.3507 mL | 5.8767 mL | |
20 mM | 0.1175 mL | 0.5877 mL | 1.1753 mL | 2.9383 mL | |
50 mM | 0.047 mL | 0.2351 mL | 0.4701 mL | 1.1753 mL | |
100 mM | 0.0235 mL | 0.1175 mL | 0.2351 mL | 0.5877 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ACT-709478 1838651-58-3 Others ACT 709478 ACT709478 Inhibitor inhibitor inhibit